This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2011 Aug;5(4):235-40.

doi: 10.5489/cuaj.11134.

Prostate cancer screening: Canadian guidelines 2011

Jonathan I Izawa¹, Laurence Klotz, D Robert Siemens, Wassim Kassouf, Alan So, John Jordan, Michael Chetner, Alla E Iansavichene

Affiliations

Affiliation

¹ Departments of Surgery & Oncology, Divisions of Urology & Surgical Oncology, The Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON;

PMID: 21801679
PMCID: PMC3147035
DOI: 10.5489/cuaj.11134

Prostate cancer screening: Canadian guidelines 2011

Jonathan I Izawa et al. Can Urol Assoc J. 2011 Aug.

. 2011 Aug;5(4):235-40.

doi: 10.5489/cuaj.11134.

Authors

Jonathan I Izawa¹, Laurence Klotz, D Robert Siemens, Wassim Kassouf, Alan So, John Jordan, Michael Chetner, Alla E Iansavichene

Affiliation

¹ Departments of Surgery & Oncology, Divisions of Urology & Surgical Oncology, The Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON;

PMID: 21801679
PMCID: PMC3147035
DOI: 10.5489/cuaj.11134

No abstract available

PubMed Disclaimer

Similar articles

Are United States and Canadian cancer screening rates consistent with guideline information regarding the age of screening initiation?
Kadiyala S, Strumpf EC. Kadiyala S, et al. Int J Qual Health Care. 2011 Dec;23(6):611-20. doi: 10.1093/intqhc/mzr050. Epub 2011 Sep 2. Int J Qual Health Care. 2011. PMID: 21890706
Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer. Canadian Prostate Health Council.
Ramsey EW, Elhilali M, Goldenberg SL, Nickel CJ, Norman R, Perreault JP, Piercy B, Trachtenberg J. Ramsey EW, et al. J Urol. 2000 Feb;163(2):499-502. J Urol. 2000. PMID: 10647665
Recent trends in prostate cancer in Canada.
LeBlanc AG, Demers A, Shaw A. LeBlanc AG, et al. Health Rep. 2019 Apr 17;30(4):12-17. doi: 10.25318/82-003-x201900400002-eng. Health Rep. 2019. PMID: 30994922
[Quality assessment of global prostate cancer screening guidelines].
Sun DQ, Cao MM, Li H, He SY, Lei L, Peng J, Li J, Chen WQ. Sun DQ, et al. Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Feb 10;42(2):227-233. doi: 10.3760/cma.j.cn112338-20200806-01033. Zhonghua Liu Xing Bing Xue Za Zhi. 2021. PMID: 33626608 Chinese.
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines.
Cabarkapa S, Perera M, McGrath S, Lawrentschuk N. Cabarkapa S, et al. Prostate Int. 2016 Dec;4(4):125-129. doi: 10.1016/j.prnil.2016.09.002. Epub 2016 Oct 8. Prostate Int. 2016. PMID: 27995110 Free PMC article. Review.

See all similar articles

Cited by

Variations in prostate biopsy practice: A quantitative questionnaire-based study.
Lipinski MO, Siemens DR, Groome PA. Lipinski MO, et al. Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E732-9. doi: 10.5489/cuaj.372. Can Urol Assoc J. 2013. PMID: 24282467 Free PMC article.
A population study of fasting time and serum prostate-specific antigen (PSA) level.
Lau CK, Guo M, Viczko JA, Naugler CT. Lau CK, et al. Asian J Androl. 2014 Sep-Oct;16(5):740-4. doi: 10.4103/1008-682X.125912. Asian J Androl. 2014. PMID: 24994780 Free PMC article.
Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.
Reece D, Kouroukis CT, Leblanc R, Sebag M, Song K, Ashkenas J. Reece D, et al. Adv Hematol. 2012;2012:621958. doi: 10.1155/2012/621958. Epub 2012 Oct 14. Adv Hematol. 2012. PMID: 23097669 Free PMC article.
Prostate-specific antigen screening can be beneficial to younger and at-risk men.
Roobol MJ, Bangma CH, Loeb S. Roobol MJ, et al. CMAJ. 2013 Jan 8;185(1):47-51. doi: 10.1503/cmaj.111962. Epub 2012 May 7. CMAJ. 2013. PMID: 22566532 Free PMC article. No abstract available.
Current prostate cancer treatment: Not what but when?
Massaro PA, Cagiannos I. Massaro PA, et al. Can Urol Assoc J. 2016 Aug;10(7-8):251-252. doi: 10.5489/cuaj.4018. Can Urol Assoc J. 2016. PMID: 27878045 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2005. Bethesda: NCI; http://seer.cancer.gov/csr/1975_2005/. Accessed July 5, 2011.
1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8. - PubMed
1. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–9. - PMC - PubMed
1. Canadian Cancer Society’s Steering Committee: Canadian Cancer Statistics 2009. Toronto: Canadian Cancer Society; 2009.
1. Dall’Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early- stage prostate cancer: a review of literature. Cancer. 2008;112:1650–9. - PubMed

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov